A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
Broad Institute researchers describe an approach they've dubbed "DNA microscopy."
So-called DNA microscopy is the latest entrant to the rapidly growing spatial genomics field that combines molecular analysis with imaging.
Findings from a genome-wide association study suggest that fetal SNPs in SLIT2 and other genes may coincide with the risk of spontaneous preterm birth.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.
After slow, organic growth in imaging, the Spanish startup is courting major healthcare companies for a buyout as the genomics market presents major opportunities.
In Science this week: transcriptional regulation of the inflammasome NLRP3, and more.
Simulated population data suggests that the lifetime risk of cervical cancer is lower for women who stop screening after a negative DNA test for oncogenic HPV.
The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.